Pharmacology and efficacy of eletriptan for the treatment of migraine attacks

International Journal of Clinical Practice

Volumn 54, Issue 10, 2000, Pages 670-674

  Diener, H C ^a   McHarg, A ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAFERGOT; ELETRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ASTHENIA; BRAIN BLOOD VESSEL; CLINICAL TRIAL; CORONARY ARTERY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; MIGRAINE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; RECURRENT DISEASE; REVIEW; SOMNOLENCE; VERTIGO;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIGRAINE DISORDERS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0034502689     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Ferrari MD, Haan J. Acute treatment of migraine attacks. Curr Opin Neural 1995; 8: 237-242.
2. Goadsby PJ, Diesen J. Diagnosis and management of migraine. BMJ 1996; 312: 1279-1282.
3. Bouchelet I, Cohen Z, Case B et al. Differential expression of sumatrip-tan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mot Pharmaco! 1996; 50: 219-223.
4. SaxenaP, Ferrari M. Pharmacology of antimigraine 5-HTi D receptor agonists. Exp Opin Invest Drugs 1996; 5: 581-593.
5. Adham N, Kao H-T, Scechter E et al. Cloning of another human serotonin receptor (S-HTin): a fifth 5-HTi receptor subtype coupled to the inhibition of adenylate cyclase. Proc Nail Acad Sci USA 1993; 90: 408-412.
6. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622-651.
7. Napier C. Stewart M, Melrose H et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H)eletriptan binding at human 5-HT,B and 5-HT|D receptors. Eur J Pharmacol 1999; 368: 259268.
8. Gupta P. Scatchard J, Shepperson NB et al. In vitro pharmacology of eletriptan (UK-116,044), a potent and selective partial agonist at the '5HT|D-like' receptor in the dog saphenous vein. Cephalalgia 1996; 16: 386.
9. IB/ID receptor agonists at the human recombinant 5-HTi and 5-HTio receptors. Br J Pharmacol 1999; 127: 93P.
10. Maassen Van Den Brink A, Van Den Broek RWM, De Vries R, Saxena PR. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan. Cephalalgia 1999; 19: 398.
11. Muir DF, McCann GP, Swan L et al. Haemodynamic and coronary effects of intravenous eletriptan, a 5-HTiB/io receptor agonist. Clin Pharmacol Ther 1999; 66: 85-90.
12. Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-II6,044): a potent and novel 5-HTiB/io receptor agonist. Eur J Pharmacol 2000; 398: 73-81.
13. Huang Z, Byan B, Matsubara T, Moskowitz MA. Time-dependent blockade of neurogenic plasma extravasation in dura mater by 5-HTiB/io agonists and endopeptidase 24.11. Br J Pharmacol 1993; 108: 331-335.
14. Milton KA, Alien MJ, Abel S et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective 'SHTio-like' receptor partial agonist. Cephalalgia 1997; 17: 414.
15. Dixon CM, Saynor DA, Andrew PD et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metab Disp 1993; 21: 761.
16. Ranee DJ, Atkinson FM, James GC et al. The pharmacokinetics of eletriptan (UK-116,044) in rat and dog. Cephalalgia 1996; 16: 387.
17. Hyland R, Jones BC, McCleverty P et al. In vitro metabolism of eletriptan in human liver microsomes. Cephalalgia 1998; 18: 404.
18. Färkkilä M, Diener HC, Dahlöf C, Steiner TJ, on behalf of the Eletriptan Steering Committee. A dose-finding study of eletriptan (5-30 mg) for the acute treatment of migraine. Cephalalgia 1996; 16: 387.
19. Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54: 156-163.
20. Steiner TJ, on behalf of the Eletriptan Steering Committee. The efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) for the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel group clinical trial. London: Migraine Trust, 1998.
21. MacGregor EA. Migraine during menstruation and the efficacy of oral eletriptan. 50th meeting of the American Academy of Neurology, Minneapolis, 1998.
22. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 532-538.
23. Pryse-Philips W, on behalf of the Eletriptan Steering Committee. Comparison of oral eletriptan (Relpax) (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acute migraine: a randomised, placebo controlled study in sumatriptan-naive patients. 9th Congress of the International Headache Society, Barcelona, 1999.
24. Reeches A, on behalf of the Eletriptan Steering Committee. Comparison of the efficacy, safety and tolerability of oral eletriptan (Relpax™) and Cafergot for the acute treatment of migraine. 9th Congress of the International Headache Society, Barcelona, 1999.